Potential use of buccal epithelium for genetic diagnosis of atherosclerosis using mtDNA mutations

Abstract

How to cite this article: Sinyov VV, Sazonova MA, Ryzhkova AI, Galitsyna EV, Melnichenko AA, Postnov AY, Orekhov AN, Grechko AV, Sobenin IA. Potential use of buccal epithelium for genetic diagnosis of atherosclerosis using mtDNA mutations. Vessel Plus 2017;1:145-50. Aim:The aim of this pilot study was to compare the heteroplasmy levels of specific mitochondrial (mt)DNA mutations in human buccal epithelial and whole blood cells in participants with different degrees of predisposition to atherosclerosis. The potential for buccal epithelium to be used for the genetic diagnosis of atherosclerosis using mtDNA mutations was assessed. Methods: Samples of buccal epithelial and whole blood cells were obtained from 134 donors. DNA was extracted from the samples and subjected to polymerase chain reaction and pyrosequencing. The threshold heteroplasmy levels of the mutations m.12315G>A, m.3336T>C, m.1555А>G, m.13513G>A, and m.3256C>T were analyzed in order to assess the potential for using buccal epithelium and whole blood for the genetic diagnosis of atherosclerosis. Results: The threshold heteroplasmy levels of the assessed mitochondrial mutations did not significantly differ between buccal epithelial and whole blood cells. Conclusion: Buccal epithelial cells may be preferable to whole blood cells for analyzing the association of mitochondrial genome mutations with atherosclerosis. Key words:Buccal cell, mutation, mtDNA, threshold heteroplasmy level, mitochondrial genome, atherosclerosis ABSTRACT Article history:

Possible Role of Mitochondrial DNA Mutations in Chronification of Inflammation: Focus on Atherosclerosis

“…Nevertheless, the results available to date position mitochondria as likely therapeutic targets for treatment of such diseases as cancer, chronic inflammatory states, and atherosclerosis. Selective mitochondria-targeting drugs, such as mitochondrial antioxidants, are being tested in preclinical and clinical trials [151,152]. Moreover, certain mtDNA mutations are being currently explored as diagnostic markers [152].…”

“…Selective mitochondria-targeting drugs, such as mitochondrial antioxidants, are being tested in preclinical and clinical trials [151,152]. Moreover, certain mtDNA mutations are being currently explored as diagnostic markers [152]. Future studies will improve our understanding of the mechanisms of mitochondrial involvement in the pathological processes.…”

Profiling of risk of subclinical atherosclerosis: possible interplay of genetic and environmental factors as the update of conventional approach

“…On the opposite, the latest findings on the role of mitochondrial DNA variation in individual predisposition to atherosclerosis provide a growing body of evidence and the expectation of the breakthrough in understanding of molecular mechanisms and pathways of atherogenesis [14,15] . Heteroplasmic mtDNA mutations represent a promising molecular biomarker of genetic susceptibility to atherosclerosis and related pathologies [16][17][18][19] . In our study, we have demonstrated that several atherosclerosis-associated mutations of mitochondrial DNA taken together as a mutation burden of mitochondrial genome possess their own explanatory power and give a significant increase atop of assessment of conventional risk factors.…”

Lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy

“…Mitochondrial dysfunction caused by mitochondrial DNA (mtDNA) damage is a well‐studied cause of cell dysfunction and death observed in atherosclerosis 7 . Correspondingly, dysfunctional mtDNA is regarded as a promising target for atherosclerosis treatment strategies.…”